Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Seletalisib shows therapeutic potential in primary Sjögren’s syndrome

19 Oct 2020

The selective PI3Kδ inhibitor seletalisib demonstrates clinical activity in patients with primary Sjögren’s syndrome (PSS) despite enrolment-related underpowering, as shown in phase II trial data.

In total, 27 patients with moderate-to-severe PSS were randomized to treatment with either seletalisib 45 mg/day (n=13; mean age, 52.2 years; 12 women) or placebo (n=14; mean age, 60.2 years; 13 women); 20 of them completed the study. The trial was terminated prematurely due to enrolment challenges with loss of statistical power (36 percent vs 80 percent planned).

At week 12, both arms showed a change in EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) score, but the reduction was greater with the study drug (difference, –2.59, 95 percent confidence interval [CI], –7.30 to 2.11; p=0.266). The change seen in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) score was also greater with seletalisib (difference, –1.55, 95 percent CI, –3.39 to 0.28).

There were no significant changes in saliva and tear flow.

In terms of safety, serious adverse events (AEs) developed in 3/13 of patients on seletalisib vs 1/14 of those on placebo. AEs led to treatment discontinuation in five and one patients, respectively. The most common event was diarrhoea.

Serum IgM and IgG concentrations markedly dropped in the seletalisib arm. The study drug produced an improvement in size and organization of salivary gland inflammatory foci and in target engagement, which therefore reduced PI3K-mTOR signaling compared with placebo.

Larger studies with specific PI3Kδ inhibitors and, potentially, with patient stratification are needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Yesterday
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 5 days ago
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).